These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Lipoxin A4 suppresses osteoclastogenesis in RAW264.7 cells and prevents ovariectomy-induced bone loss. Liu C; Guan H; Cai C; Li F; Xiao J Exp Cell Res; 2017 Mar; 352(2):293-303. PubMed ID: 28209487 [TBL] [Abstract][Full Text] [Related]
3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways. Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253 [TBL] [Abstract][Full Text] [Related]
4. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways. Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972 [TBL] [Abstract][Full Text] [Related]
5. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways. Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053 [TBL] [Abstract][Full Text] [Related]
6. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts. Kim MH; Ryu SY; Choi JS; Min YK; Kim SH J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo. Franco GC; Kajiya M; Nakanishi T; Ohta K; Rosalen PL; Groppo FC; Ernst CW; Boyesen JL; Bartlett JD; Stashenko P; Taubman MA; Kawai T Exp Cell Res; 2011 Jun; 317(10):1454-64. PubMed ID: 21420951 [TBL] [Abstract][Full Text] [Related]
8. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis. Gong W; Dou H; Liu X; Sun L; Hou Y Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134 [TBL] [Abstract][Full Text] [Related]
10. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways. Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759 [TBL] [Abstract][Full Text] [Related]
11. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways. Song J; Jing Z; Hu W; Yu J; Cui X Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958 [TBL] [Abstract][Full Text] [Related]
12. Yukmijihwang-tang inhibits receptor activator for nuclear Factor-κB ligand-induced osteoclast differentiation. Shim KS; Ma CJ; Kim DS; Ma JY J Med Food; 2011 Nov; 14(11):1439-47. PubMed ID: 21883017 [TBL] [Abstract][Full Text] [Related]
13. Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity. Ang ES; Pavlos NJ; Chai LY; Qi M; Cheng TS; Steer JH; Joyce DA; Zheng MH; Xu J J Cell Physiol; 2009 Dec; 221(3):642-9. PubMed ID: 19681045 [TBL] [Abstract][Full Text] [Related]
14. Neohesperidin suppresses osteoclast differentiation, bone resorption and ovariectomised-induced osteoporosis in mice. Tan Z; Cheng J; Liu Q; Zhou L; Kenny J; Wang T; Lin X; Yuan J; Quinn JMW; Tickner J; Hong G; Qin A; Zhao J; Xu J Mol Cell Endocrinol; 2017 Jan; 439():369-378. PubMed ID: 27664516 [TBL] [Abstract][Full Text] [Related]
15. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB. Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321 [TBL] [Abstract][Full Text] [Related]
16. Afamin stimulates osteoclastogenesis and bone resorption via Gi-coupled receptor and Ca2+/calmodulin-dependent protein kinase (CaMK) pathways. Kim BJ; Lee YS; Lee SY; Park SY; Dieplinger H; Yea K; Lee SH; Koh JM; Kim GS J Endocrinol Invest; 2013 Nov; 36(10):876-82. PubMed ID: 23698732 [TBL] [Abstract][Full Text] [Related]
17. Sargachromanol G inhibits osteoclastogenesis by suppressing the activation NF-κB and MAPKs in RANKL-induced RAW 264.7 cells. Yoon WJ; Kim KN; Heo SJ; Han SC; Kim J; Ko YJ; Kang HK; Yoo ES Biochem Biophys Res Commun; 2013 May; 434(4):892-7. PubMed ID: 23611776 [TBL] [Abstract][Full Text] [Related]
18. Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells than eicosapentaenoic acid. Rahman MM; Bhattacharya A; Fernandes G J Cell Physiol; 2008 Jan; 214(1):201-9. PubMed ID: 17929247 [TBL] [Abstract][Full Text] [Related]
19. Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss. Zhu M; Liu H; Sun K; Liu J; Mou Y; Qi D; Zhou C; Abudunaibi M; Tasiken B; Li J; Cheng H; Huang H Biomed Pharmacother; 2020 Mar; 123():109769. PubMed ID: 31846839 [TBL] [Abstract][Full Text] [Related]
20. High throughput screening identified a substituted imidazole as a novel RANK pathway-selective osteoclastogenesis inhibitor. Chen T; Knapp AC; Wu Y; Huang J; Lynch JS; Dickson JK; Lawrence RM; Feyen JH; Agler ML Assay Drug Dev Technol; 2006 Aug; 4(4):387-96. PubMed ID: 16945012 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]